Using biotechnology to reduce antibiotic resistance
The solution to reducing the use of antibiotics may lie in biotechnology. Yeast derivatives, glucans and prebiotics used strategically together to be more precise.
BY JOÃO FERNANDO ALBERS KOCH, BIORIGIN GLOBAL TECHNICAL AND PRODUCT MANAGER
P
ig production is even more technified and producers are increasingly aware of biosafety issues and improvements in management and nutrition to achieve higher productive and zootechnical results.
However, the control of bacterial resistance to antibiotics and the global recommendation on the reduction on the use of antibiotics as growth promoters, can become a challenge to the producer. The antibiotic ban in feed triggers a demand for alternatives such as feed ingredients, additives, and prebiotics. Although there is a range of additives available in the animal nutrition market today, there is a need to define strategic programmes focused on immune nutrition and intestinal functionality that allow the control of bacteria resistance and reduction of antibiotic use to keep animal health and productivity.
Biotechnological solutions To bring a natural solution to the pig market, focussed on the reduction of bacterial antibiotic resistance, Biorigin developed the BioProtect Program where three biotechnological solutions from Biorigin were strategically applied: MacroGard (highly purified β-glucan), HyperGen (second generation prebiotic) and ActiveMOS (prebiotic). A study was conducted in a commercial pig farm under the coordination of Animal Nutri Research Centre (Brazil, 2020), including 480 piglets during grower and finisher phases – between 63 to 172 days of life. The objective was to evaluate the effect of yeast derivatives as a strategical programme in piglets zootechnical and health response under the total removal of antibiotics as growth promoters and under the reduction of the use of antibiotics in therapeutic dosages. The study followed a specific programme (Table 1). The difference between the control and overdose groups is the antibiotic
(therapeutic and growth-promoter) dosage. In the control group the dosage indicated in the label of the products was used and in the overdose group an increment of 30% in the antibiotic dosage was considered. Note that on BioProtect Program there are only two periods of 14 days with therapeutic antibiotic treatment. Total exclusion of antibiotic as growth promoter: no AGP during the entire grower and finisher periods in Biorigin’ s Program!
The results showed that the BioProtect Program: • allowed total removal of antibiotics as growth promoter • reduced the number of feed therapeutic antibiotic supplementation
• maintained piglets’ weight gain in the period • maintained the feed conversion rate • reduced diarrhoea during grower and finisher phases It has been proven that S. cerevisiae yeast derivatives are strategic technologies to build effective feed programmes, acting on intestinal functionality and immunomodulation, promoting an important reduction in the use of antibiotics, favouring intestinal health, strengthened natural defences, and ensuring animal performance and well-being. The programme allowed the total removal of growth-promoter antibiotics and reduce therapeutic antibiotic use, keeping animal performance and improving animal health.
For more information please contact: biorigin@
biorigin.net
Table 1 -BioProtect feed program and study groups. Phase
Period Days of life
Treatment Control
Overdose
BioProtect Program
Grower 1 14 days 63 – 76
Therapeutic antibiotic
Therapeutic antibiotic
Grower 2 20 days 77 – 98
AGP 1 AGP 2 Therapeutic HyperGen
Grower 3 14 days
99 – 113
Therapeutic antibiotic
Therapeutic antibiotic
HyperGen (1.0Kg/MT)
Grower 4 Finisher 1 20 days
14 days 114 – 135 136 – 150
AGP 1 Therapeutic antibiotic
AGP 2 Therapeutic antibiotic
antibiotic + (1.0Kg/MT) (300g/MT) + (1.5Kg/MT) antibiotic + MacroGard (300g/MT)
MacroGard (300g/MT)
Therapeutic antibiotic: Tiamulin (200 ppm) + Amoxicillin (440 ppm). AGP 1: Antibiotic growth-promoter, Control group: Enramycin 10 ppm (grower phase) and Enramycin 5 ppm (finisher phase). AGP 2: Antibiotic growth-promoter, Overdose group: Enramycin 13 ppm (grower phase) and Enramycin 6,5 ppm (finisher phase).
▶ ANTIBIOTIC REDUCTION | DECEMBER 2021 35
Finisher 2 20 days
151 – 172 AGP 1 AGP 2
MacroGard ActiveMOS Therapeutic ActiveMOS (1.5Kg/MT)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96
